In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation

Purpose: Hepatocellular carcinoma (HCC) resistance to sorafenib treatment and other treatment strategies causes a higher mortality rate in patients diagnosed with HCC.Research question.HCC often develops resistance to sorafenib treatment and other therapies, leading to increased mortality rates in d...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Aya Anis, Ahmed M. Mostafa, Mariam S. Kerema, Nadia M. Hamdy, Ahmed S. Sultan
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-12-01
Edice:	Journal of Genetic Engineering and Biotechnology
Témata:	Rosiglitazone Insulin IBMX, PPARγ HCC Sorafenib Adipogenesis-inducer
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1687157X2400132X
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!